Search

… ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome LEIDEN, Netherlands & … there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated … relating to our announcement of results from our QR-421a clinical trial, and the clinical development and the …

… a Phase 1b safety, tolerability and exploratory efficacy trial. Top-line data to be reported in mid-2017 Top-line data from a previous clinical trial demonstrated that QR-010 restores CFTR …

… has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, a novel investigational RNA … of CF. We are very pleased to participate in the first clinical trial for this novel compound," said Professor Stuart Elborn …

… ProQR Announces Clinical Data Presentations and Investor & Analyst Event at … from the nasal potential difference (NPD) proof of concept clinical trial (PQ-010-002) of lead program, QR-010, in subjects with …

… and an overview of the objectives of the Phase 1/2 Stellar trial of QR-421a. Event Details Date/Time: February 22, 2021, … He was funded by the Foundation Fighting Blindness (FFB) Clinical Research Fellowship Award, FFB Career Development … on numerous gene therapy and neuroprotection clinical trials for inherited retinal degenerations. Dr. Yang …

… to receive ODD from the FDA and EMA.  A first-in-human clinical trial of QR-313 is expected to be initiated in 2018, with …

… of the Scientific Advisory Board to investigate the clinical value of the approach in a scientifically rigorous manner.” Thaddeus (Ted) Dryja, M.D. is a Clinical Professor of Ophthalmology at Harvard Medical School … discovery and development of our pipeline, including our clinical trials and timing of results and the advancement of …

… forward to beginning enrollment in the Phase 1/2 (Aurora) clinical trial for QR-1123 in the coming months.” About QR-1123 …

… receive ODD in the U.S. The Company will be presenting pre-clinical data for QR-313 at two European scientific … is designed for topical administration. A first-in-human clinical trial of QR-313 will be initiated in 2018. Clinical data from …

… Amaurosis 10 Access based on positive interim analysis of clinical data as well as preclinical data to date  PRIME … the interim safety and efficacy data from our Phase 1/2 clinical trial that demonstrated meaningful improvements in vision …